Literature DB >> 24521728

High linkage to care in a community-based rapid HIV testing and counseling project among men who have sex with men in Copenhagen.

Tavs Qvist1, Susan Alice Cowan, Christian Graugaard, Marie Helleberg.   

Abstract

INTRODUCTION: The aim of the study was to evaluate a community-based human immunodeficiency virus (HIV) testing program for its capacity to reach men who have sex with men (MSM) and successfully refer HIV-positive patients to treatment.
METHODS: A walk-in clinic placed in the heart of the Copenhagen MSM community provided sexually transmitted infection counseling and rapid HIV testing. In addition, syphilis testing and hepatitis B vaccination were offered. The clinic was staffed with specially trained, predominantly non-health care personnel, and services were anonymous and free of charge.
RESULTS: A total of 3012 HIV tests with concomitant counseling were performed between 2008 and 2012. The median age of users was 33 years (range, 16-73 years), 18% were non-Danish citizens, and 12% reported that this was their first HIV test. Thirty-eight individuals tested positive; however, 1 was found to be false positive by routine confirmatory testing. The remaining 37 users were true positive. All but 1 user was successfully linked to care at an infectious disease department and achieved full viral suppression after a median of 8 months (interquartile range, 5-19 months). The 37 positive patients accounted for 11% of all newly diagnosed HIV cases among MSM in Copenhagen in the period covered. Patients diagnosed in Checkpoint were younger than other newly diagnosed MSM, but had similar median CD4 counts at the time of diagnosis (420 [interquartile range, 260-590]). Seventy-six MSM (3%) were found syphilis positive in rapid testing and referred for confirmatory testing. Furthermore, 264 MSM completed a 3-shot hepatitis B vaccination program.
CONCLUSIONS: Easily accessible, community walk-in clinics and targeted testing in high-risk settings are convenient for populations of MSM less likely to seek out the established health care system. Checkpoint diagnosed 37 new HIV cases, posed no barrier to successful linkage to care, was noninferior in quickly reducing community viral load, was cost-effective, reached younger MSM, and proved an ideal platform for trying out new interventions and test forms, which conventional health care providers have not yet embraced.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24521728     DOI: 10.1097/OLQ.0000000000000096

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  13 in total

1.  Acceptability of Rapid HIV Testing Among Latinos in Washington Heights, New York City, New York, USA.

Authors:  Tawandra L Rowell-Cunsolo; Yamnia I Cortes; Yue Long; Erida Castro-Rivas; Jianfang Liu
Journal:  J Immigr Minor Health       Date:  2017-08

2.  Testing the hypothesis that treatment can eliminate HIV: a nationwide, population-based study of the Danish HIV epidemic in men who have sex with men.

Authors:  Justin T Okano; Danielle Robbins; Laurence Palk; Jan Gerstoft; Niels Obel; Sally Blower
Journal:  Lancet Infect Dis       Date:  2016-05-09       Impact factor: 25.071

Review 3.  Facilitators and barriers in HIV linkage to care interventions: a qualitative evidence review.

Authors:  Lai Sze Tso; John Best; Rachel Beanland; Meg Doherty; Mellanye Lackey; Qingyan Ma; Brian J Hall; Bin Yang; Joseph D Tucker
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

4.  The Lisbon Cohort of men who have sex with men.

Authors:  Paula Meireles; Raquel Lucas; Ana Martins; Ana Cláudia Carvalho; Ricardo Fuertes; João Brito; Maria José Campos; Luís Mendão; Henrique Barros
Journal:  BMJ Open       Date:  2015-05-12       Impact factor: 2.692

5.  COBA-Cohort: a prospective cohort of HIV-negative men who have sex with men, attending community-based HIV testing services in five European countries (a study protocol).

Authors:  Nicolas Lorente; Laura Fernàndez-López; Ricardo Fuertes; Daniela Rojas Castro; François Pichon; Bojan Cigan; Sophocles Chanos; Paula Meireles; Raquel Lucas; Stéphane Morel; Per Slaaen Kaye; Cristina Agustí; Irena Klavs; Tom Platteau; Jordi Casabona
Journal:  BMJ Open       Date:  2016-07-13       Impact factor: 2.692

6.  Improving prevention and care for HIV and sexually transmitted infections among men who have sex with men in Cambodia: the sustainable action against HIV and AIDS in communities (SAHACOM).

Authors:  Siyan Yi; Sovannary Tuot; Pheak Chhoun; Khuondyla Pal; Chanrith Ngin; Sok Chamreun Choub; Carinne Brody
Journal:  BMC Health Serv Res       Date:  2016-10-21       Impact factor: 2.655

7.  Enhancing HIV Testing and Treatment among Men Who Have Sex with Men in China: A Pilot Model with Two-Rapid Tests, Single Blood Draw Session, and Intensified Case Management in Six Cities in 2013.

Authors:  Dapeng Zhang; Hongyan Lu; Minghua Zhuang; Guohui Wu; Hongjing Yan; Jun Xu; Xiaoli Wei; Chengmei Li; Sining Meng; Xiaojing Fu; Jinlei Qi; Peng Wang; Mei Luo; Min Dai; Ray Yip; Jiangping Sun; Zunyou Wu
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

8.  Monitoring progress towards the first UNAIDS 90-90-90 target in key populations living with HIV in Norway.

Authors:  Robert Whittaker; Kelsey K Case; Øivind Nilsen; Hans Blystad; Susan Cowan; Hilde Kløvstad; Ard van Sighem
Journal:  BMC Infect Dis       Date:  2020-06-26       Impact factor: 3.090

Review 9.  Measures and Metrics for Feasibility of Proof-of-Concept Studies With Human Immunodeficiency Virus Rapid Point-of-Care Technologies: The Evidence and the Framework.

Authors:  Nitika Pant Pai; Tiago Chiavegatti; Rohit Vijh; Nicolaos Karatzas; Jana Daher; Megan Smallwood; Tom Wong; Nora Engel
Journal:  Point Care       Date:  2017-11-14

10.  Are there any differences between different testing sites? A cross-sectional study of a Norwegian low-threshold HIV testing service for men who have sex with men.

Authors:  Bera Ulstein Moseng; Vegar Bjørnshagen
Journal:  BMJ Open       Date:  2017-10-06       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.